Maxigen Biotech Inc. (TPE:1783)

Maxigen Biotech Statistics

Total Valuation

Maxigen Biotech has a market cap or net worth of TWD 3.78 billion. The enterprise value is 3.05 billion.

Market Cap	3.78B
Enterprise Value	3.05B

Important Dates

The next estimated earnings date is Friday, March 20, 2026.

Earnings Date	Mar 20, 2026
Ex-Dividend Date	Sep 5, 2025

Share Statistics

Maxigen Biotech has 80.69 million shares outstanding. The number of shares has increased by 0.62% in one year.

Current Share Class	80.69M
Shares Outstanding	80.69M
Shares Change (YoY)	+0.62%
Shares Change (QoQ)	-49.78%
Owned by Insiders (%)	0.97%
Owned by Institutions (%)	2.24%
Float	35.76M

Valuation Ratios

The trailing PE ratio is 18.07.

PE Ratio	18.07
Forward PE	n/a
PS Ratio	4.77
PB Ratio	2.56
P/TBV Ratio	2.56
P/FCF Ratio	16.89
P/OCF Ratio	13.63
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.35, with an EV/FCF ratio of 13.62.

EV / Earnings	13.01
EV / Sales	3.84
EV / EBITDA	11.35
EV / EBIT	12.75
EV / FCF	13.62

Financial Position

The company has a current ratio of 4.19

Current Ratio	4.19
Quick Ratio	3.77
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 16.67% and return on invested capital (ROIC) is 29.05%.

Return on Equity (ROE)	16.67%
Return on Assets (ROA)	9.21%
Return on Invested Capital (ROIC)	29.05%
Return on Capital Employed (ROCE)	16.12%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.49
Inventory Turnover	3.10

Taxes

In the past 12 months, Maxigen Biotech has paid 37.45 million in taxes.

Income Tax	37.45M
Effective Tax Rate	13.79%

Stock Price Statistics

The stock price has decreased by -10.04% in the last 52 weeks. The beta is 0.23, so Maxigen Biotech's price volatility has been lower than the market average.

Beta (5Y)	0.23
52-Week Price Change	-10.04%
50-Day Moving Average	43.71
200-Day Moving Average	43.55
Relative Strength Index (RSI)	66.61
Average Volume (20 Days)	128,894

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Maxigen Biotech had revenue of TWD 792.49 million and earned 234.07 million in profits. Earnings per share was 2.59.

Revenue	792.49M
Gross Profit	549.45M
Operating Income	238.80M
Pretax Income	271.52M
Net Income	234.07M
EBITDA	268.38M
EBIT	238.80M
Earnings Per Share (EPS)	2.59

Balance Sheet

The company has 731.12 million in cash and n/a in debt, with a net cash position of 731.12 million or 9.06 per share.

Cash & Cash Equivalents	731.12M
Total Debt	n/a
Net Cash	731.12M
Net Cash Per Share	9.06
Equity (Book Value)	1.47B
Book Value Per Share	16.43
Working Capital	723.59M

Cash Flow

In the last 12 months, operating cash flow was 276.97 million and capital expenditures -53.43 million, giving a free cash flow of 223.54 million.

Operating Cash Flow	276.97M
Capital Expenditures	-53.43M
Free Cash Flow	223.54M
FCF Per Share	2.77

Margins

Gross margin is 69.33%, with operating and profit margins of 30.13% and 29.54%.

Gross Margin	69.33%
Operating Margin	30.13%
Pretax Margin	34.26%
Profit Margin	29.54%
EBITDA Margin	33.86%
EBIT Margin	30.13%
FCF Margin	28.21%

Dividends & Yields

This stock pays an annual dividend of 0.83, which amounts to a dividend yield of 1.79%.

Dividend Per Share	0.83
Dividend Yield	1.79%
Dividend Growth (YoY)	-16.90%
Years of Dividend Growth	n/a
Payout Ratio	31.80%
Buyback Yield	-0.62%
Shareholder Yield	1.17%
Earnings Yield	6.20%
FCF Yield	5.92%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on September 7, 2023. It was a forward split with a ratio of 1.05.

Last Split Date	Sep 7, 2023
Split Type	Forward
Split Ratio	1.05

Scores

Maxigen Biotech has an Altman Z-Score of 11.97 and a Piotroski F-Score of 6.

Altman Z-Score	11.97
Piotroski F-Score	6